MBL
MBL is committed to being a leading manufacturer & supplier of diagnostic reagents that facilitate further advances in personalized medicine & individualization of medical care
News releases
-
Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
-
MBL Launches a Kit for Simultaneous Detection of SARS-CoV-2 and Influenza Virus Antigens
This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic method.
-
MBL Obtained European Quality Management System Certificate (IVDR)
The certification ensures that the CE marked diagnostic products supplied by MBL adhere to standards of quality and safety that ensure the highest level of patients’ health protection
-
MEBGEN BRAF Kit Receives MHLW Approval as Companion Diagnostic for Use with Patients with Melanoma
MBL announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare for production ...
-
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
-
MBL Launches Five-test Kit for Rapid SARS-CoV-2 Antigen Detection
This product is a five-test kit version of GLINE-2019-nCoV Ag Kit (Code No. YH-G86256) which was released on February 14th as a one test kit